Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tenecteplase (TNK) in Intracerebral Hemorrhage (ICH)
NCT06696131Phase 1Not yet recruiting
- Start
- Sep 2026
- Primary completion
- Jan 2028
- Modality
- rProtein (Recombinant Protein), Biologic
01
Overview
Phase 1, open-label, single-arm trial of tenecteplase in intracerebral hemorrhage (ICH). Primary endpoints: Safety Assessment at 30 days and Adverse Event Evaluation at 30 days. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
tenecteplase
03
Conditions
intracerebral hemorrhage (ICH)
Beyond the preview
Go deeper on NCT06696131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06696131.